NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Feb. 20, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc
Source: www.prnewswire.com
AbbVie and Voyager Therapeutics Inc. have inked a partnership to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer’s and other neurodegenerative diseases. This collaboration combines the synergies of both companies such that AbbVie’s will utilize monoclonal antibody expertise, global clinical development and commercial capabilities with Voyager’s gene therapy platform and expertise that enables generating adeno-associated viral (AAV) vectors for the treatment of neurodegenerative diseases. Under the terms of the collaboration and option agreement, Voyager will receive an upfront cash payment of $69 million and up to $155 million in potential preclinical and Phase 1 option payments. Additionally, Voyager is eligible to receive up to $895 million in development and regulatory milestones for each vectorized tau antibody compound and is eligible to receive tiered royalties on the global commercial net sales of the vectorized antibodies for tauopathies, including Alzheimer’s disease and other neurodegenerative diseases.
